GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » Revenue

Vivos Therapeutics (Vivos Therapeutics) Revenue : $13.80 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics Revenue?

Vivos Therapeutics's revenue for the three months ended in Dec. 2023 was $3.25 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $13.80 Mil. Vivos Therapeutics's Revenue per Share for the three months ended in Dec. 2023 was $2.29. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $11.77.

Warning Sign:

Vivos Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of Vivos Therapeutics was -34.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -23.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 6 years, Vivos Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 54.80% per year. The lowest was -23.60% per year. And the median was 2.60% per year.


Vivos Therapeutics Revenue Historical Data

The historical data trend for Vivos Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics Revenue Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 11.39 13.07 16.89 16.02 13.80

Vivos Therapeutics Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.95 3.86 3.40 3.30 3.25

Competitive Comparison of Vivos Therapeutics's Revenue

For the Medical Devices subindustry, Vivos Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivos Therapeutics's Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Vivos Therapeutics's Revenue falls into.



Vivos Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivos Therapeutics  (NAS:VVOS) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Vivos Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Therapeutics (Vivos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
Executives
Ronald Kirk Huntsman director, 10 percent owner, officer: Chairman & CEO 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman officer: Chief Financial Officer 6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow director REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson director 2 MUSICK, IRVINE CA 92618
Anja B Krammer director C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh director, 10 percent owner, officer: Chief Medical Officer 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129